Eventide Asset Management, LLC Alx Oncology Holdings Inc Transaction History

Eventide Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$4.52 - $11.71 $1.07 Million - $2.78 Million	-237,171 Reduced 26.29%	664,829 $3.01 Million
Q3 2022 Nov 14, 2022	BUY	$8.23 - $15.14 $7.42 Million - $13.7 Million	902,000 New	902,000 $8.63 Million
Q3 2021 Nov 15, 2021	SELL	$52.51 - $80.91 $23.1 Million - $35.6 Million	-439,950 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$52.2 - $75.23 $18.3 Million - $26.3 Million	349,950 Added 388.83%	439,950 $24.1 Million
Q1 2021 May 14, 2021	BUY	$62.84 - $87.68 $5.66 Million - $7.89 Million	90,000 New	90,000 $6.64 Million

101

39.7M

134K

17.4K

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $68.9M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.